PLX · CIK 0001006281 · operating
Protalix BioTherapeutics is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company's marketed products include Elelyso for Gaucher disease treatment and Elfabrio for adult Fabry disease patients. The company is also advancing two clinical-stage candidates: PRX-115, a PEGylated recombinant uricase in Phase 2 development for gout, and PRX-119, a PEGylated recombinant human DNase I product for neutrophil extracellular trap-related diseases.
Protalix maintains strategic partnerships with Pfizer, Chiesi Farmaceutici, Secarna Pharmaceuticals, and Fundação Oswaldo Cruz. The company operates with 213 full-time employees and maintains a geographic presence across the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. Headquarters are located in Hackensack, New Jersey.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $0.04 | $0.04 | -55.6% | |
| 2023 | $0.09 | $0.12 | +129.0% | |
| 2022 | $-0.31 | $-0.31 | +50.0% | |
| 2021 | $-0.62 | $-0.62 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-17 | 0001558370-25-003039 | SEC ↗ |
| 2023-12-31 | 2024-03-14 | 0001558370-24-003161 | SEC ↗ |
| 2022-12-31 | 2023-02-27 | 0001558370-23-002102 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001558370-22-004823 | SEC ↗ |
| 2020-12-31 | 2021-03-30 | 0001558370-21-003681 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001104659-20-032540 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001144204-19-014464 | SEC ↗ |
| 2017-12-31 | 2018-03-06 | 0001144204-18-013053 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001144204-17-015083 | SEC ↗ |
| 2015-12-31 | 2016-03-08 | 0001144204-16-086642 | SEC ↗ |
| 2014-12-31 | 2015-03-12 | 0001144204-15-015672 | SEC ↗ |
| 2013-12-31 | 2014-03-13 | 0001144204-14-015468 | SEC ↗ |
| 2012-12-31 | 2013-02-28 | 0001144204-13-012065 | SEC ↗ |
| 2011-12-31 | 2012-02-27 | 0001144204-12-011082 | SEC ↗ |
| 2010-12-31 | 2011-02-23 | 0000950123-11-017213 | SEC ↗ |
| 2009-12-31 | 2010-02-26 | 0000950123-10-017277 | SEC ↗ |
| 2008-12-31 | 2009-03-06 | 0000950123-09-004203 | SEC ↗ |
| 2007-12-31 | 2008-03-17 | 0000950136-08-001374 | SEC ↗ |
| 2006-12-31 | 2007-03-30 | 0000891092-07-001189 | SEC ↗ |
| 2005-12-31 | 2006-03-30 | 0001006281-06-000002 | SEC ↗ |
| 2004-12-31 | 2005-03-31 | 0001006281-05-000001 | SEC ↗ |
| 2003-12-31 | 2004-03-30 | 0001006281-04-000003 | SEC ↗ |
| 2002-12-31 | 2003-03-28 | 0001006281-03-000002 | SEC ↗ |